Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Blessing, John A
679  Ergebnisse:
Personensuche X
?
1

A Phase II evaluation of ixabepilone (IND #59699, NSC #7104..:

Duska, Linda R. ; Blessing, John A. ; Rotmensch, Jacob...
Gynecologic Oncology.  135 (2014)  1 - p. 44-48 , 2014
Link: https://doi.org/10.1016/..
 
?
2

Gynecologic oncology group strategies to improve timeliness..:

Bialy, Sally ; Blessing, John A ; Stehman, Frederick B..
Clinical Trials.  10 (2013)  4 - p. 617-623 , 2013
Link: https://doi.org/10.1177/..
 
?
3

Phase II trial of nab-paclitaxel in the treatment of recurr..:

Alberts, David S. ; Blessing, John A. ; Landrum, Lisa M....
Gynecologic Oncology.  127 (2012)  3 - p. 451-455 , 2012
Link: https://doi.org/10.1016/..
 
?
4

A phase II evaluation of trabectedin in the treatment of ad..:

Monk, Bradley J. ; Blessing, John A. ; Street, Daron G....
Gynecologic Oncology.  124 (2012)  1 - p. 48-52 , 2012
Link: https://doi.org/10.1016/..
 
?
5

A phase II evaluation of belinostat and carboplatin in the ..:

Dizon, Don S. ; Blessing, John A. ; Penson, Richard T....
Gynecologic Oncology.  125 (2012)  2 - p. 367-371 , 2012
Link: https://doi.org/10.1016/..
 
?
6

A phase II study of gemcitabine (gemzar, LY188011) in the t..:

Tait, David L. ; Blessing, John A. ; Hoffman, James S....
Gynecologic Oncology.  121 (2011)  1 - p. 118-121 , 2011
Link: https://doi.org/10.1016/..
 
?
7

Gynecologic Oncology Group quality assurance audits: analys..:

Blessing, John A ; Bialy, Sally A ; Whitney, Charles W..
Clinical Trials.  7 (2010)  4 - p. 390-399 , 2010
Link: https://doi.org/10.1177/..
 
?
8

A phase II evaluation of weekly gemcitabine and docetaxel f..:

Miller, Brigitte E. ; Blessing, John A. ; Stehman, Frederick B....
Gynecologic Oncology.  118 (2010)  2 - p. 139-144 , 2010
Link: https://doi.org/10.1016/..
 
?
9

A phase II evaluation of bortezomib in the treatment of rec..:

Aghajanian, Carol ; Blessing, John A. ; Darcy, Kathleen M....
Gynecologic Oncology.  115 (2009)  2 - p. 215-220 , 2009
Link: https://doi.org/10.1016/..
 
?
10

A phase II evaluation of pemetrexed (Alimta, LY231514, IND ..:

Miller, David Scott ; Blessing, John A. ; Drake, Richard D....
Gynecologic Oncology.  115 (2009)  3 - p. 443-446 , 2009
Link: https://doi.org/10.1016/..
 
?
11

A Phase II evaluation of weekly topotecan as a single agent..:

Fiorica, James V. ; Blessing, John A. ; Puneky, Louis V....
Gynecologic Oncology.  115 (2009)  2 - p. 285-289 , 2009
Link: https://doi.org/10.1016/..
 
?
12

Fixed-dose rate gemcitabine plus docetaxel as second-line t..:

Hensley, Martee L. ; Blessing, John A. ; DeGeest, Koen...
Gynecologic Oncology.  109 (2008)  3 - p. 323-328 , 2008
Link: https://doi.org/10.1016/..
 
?
13

Phase II trial of cetuximab and carboplatin in relapsed pla..:

Secord, Angeles Alvarez ; Blessing, John A. ; Armstrong, Deborah K....
Gynecologic Oncology.  108 (2008)  3 - p. 493-499 , 2008
Link: https://doi.org/10.1016/..
 
?
14

Fixed-dose rate gemcitabine plus docetaxel as first-line th..:

Hensley, Martee L. ; Blessing, John A. ; Mannel, Robert.
Gynecologic Oncology.  109 (2008)  3 - p. 329-334 , 2008
Link: https://doi.org/10.1016/..
 
?
15

Evaluation of pemetrexed (Alimta, LY231514) as second line ..:

Miller, David Scott ; Blessing, John A. ; Bodurka, Diane C...
Gynecologic Oncology.  110 (2008)  1 - p. 65-70 , 2008
Link: https://doi.org/10.1016/..
 
1-15